![office 2016 mail merge document not transferring currencies office 2016 mail merge document not transferring currencies](https://venturebeat.com/wp-content/uploads/2017/12/uspresidentssiri.jpg)
The attorney reported many of the discoveries in the FDA petition, and Schrag sent all of them to the National Institutes of Health (NIH), which had invested tens of millions of dollars in the work. He identified apparently altered or duplicated images in dozens of journal articles. So he applied his technical and medical knowledge to interrogate published images about the drug and its underlying science-for which the attorney paid him $18,000.
![office 2016 mail merge document not transferring currencies office 2016 mail merge document not transferring currencies](http://www.urban75.org/blog/images/comacchio-ferrera-italy-13.jpg)
He feared volunteers in ongoing Simufilam trials faced risks of side effects with no chance of benefit. His own research also contradicted some of Cassava’s claims. Schrag, 37, a softspoken, nonchalantly rumpled junior professor, had already gained some notoriety by publicly criticizing the controversial FDA approval of the anti-Aβ drug Aduhelm. The attorney’s clients-two prominent neuroscientists who are also short sellers who profit if the company’s stock falls-believed some research related to Simufilam may have been “fraudulent,” according to a petition later filed on their behalf with the U.S. The drug’s developer, Cassava Sciences, claimed it improved cognition, partly by repairing a protein that can block sticky brain deposits of the protein amyloid beta (Aβ), a hallmark of Alzheimer’s.
![office 2016 mail merge document not transferring currencies office 2016 mail merge document not transferring currencies](https://venturebeat.com/wp-content/uploads/2018/05/2018052516064300-e7260330e4b7d47c63ff99ba9689d77c.jpg)
A colleague wanted to connect him with an attorney investigating an experimental drug for Alzheimer’s disease called Simufilam. In August 2021, Matthew Schrag, a neuroscientist and physician at Vanderbilt University, got a call that would plunge him into a maelstrom of possible scientific misconduct. A version of this story appeared in Science, Vol 377, Issue 6604.